Physician profile
Jane E Nelson
NPI 1790751428
$683.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $151.42 | 2019-2020 | |
| Novo Nordisk INC | $112.29 | 2019-2020 | |
| Lilly USA, LLC | $64.74 | 2019-2020 | |
| Pfizer INC. | $50.30 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.60 | 2019 | |
| Boston Scientific Corporation | $36.95 | 2019 | |
| Astellas Pharma US INC | $31.12 | 2019 | |
| Merck Sharp & Dohme LLC | $26.20 | 2019 | |
| Duchesnay USA Incorporated | $24.37 | 2019 | |
| Aytu Biopharma, INC. | $24.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.42 | 2019 | |
| Gilead Sciences, INC. | $23.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2019 | |
| Abbott Laboratories | $19.69 | 2020 | |
| Ironshore Pharmaceuticals INC. | $19.14 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $15.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.